Impact of Bronchiectasis on Healthcare Resource Utilization and Direct Medical Costs of Managing Comorbid Chronic Obstructive Pulmonary Disease, Asthma, and Rheumatoid Arthritis in the United States
The Clinical Respiratory Journal · 2025
DOI: 10.1111/crj.70150 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Clinical Respiratory Journal, 2025. Verfasst von Maitreyee Mohanty und 7 weiteren Autor:innen. Beteiligte Einrichtung: Insmed Incorporated, Bridgewater, New Jersey, USA. Hauptthemen laut MEDLINE: Bronchiectasis, Arthritis, Rheumatoid, Asthma, Pulmonary Disease, Chronic Obstructive. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, Insmed Incorporated.
Themen: COPD
Abstract (Originalsprache)
Background
Although patients with bronchiectasis often have comorbidities, the impact of bronchiectasis on managing these is unknown. This study assessed the incremental burden of managing chronic obstructive pulmonary disease (COPD), asthma, and rheumatoid arthritis in patients with bronchiectasis.
Methods
This retrospective cohort study using Merative MarketScan US claims data included patients with a COPD, asthma, or rheumatoid arthritis diagnosis between January 2017 and December 2021. Within these cohorts, patients with a bronchiectasis diagnosis (excluding cystic fibrosis) were compared with nonbronchiectasis controls following 1:1 propensity score matching (1:2 for rheumatoid arthritis). Comorbid disease‐specific inpatient, outpatient, and emergency room (ER) visits and direct medical costs were reported.
Results
After matching, 4291 patients with COPD, 2460 with asthma, and 566 with rheumatoid arthritis, all with bronchiectasis, and the corresponding controls, were included. For patients with COPD, proportions with COPD‐related outpatient (66.5% vs. 56.8%), ER (7.5% vs. 5.8%), and inpatient visits (4.5% vs. 3.1%), as well as respiratory‐related ($11 054 vs. $6961) and disease‐specific ($1384 vs. $1107) costs were significantly higher in the bronchiectasis cohort (vs. control cohort). For patients with asthma, asthma‐related outpatient visits (52.0% vs. 41.1%), respiratory‐related ($10 327 vs. $5458), and disease‐specific ($489 vs. $221) costs were significantly higher in the bronchiectasis cohort. For patients with rheumatoid arthritis, rheumatoid arthritis‐specific PPPY outpatient (5.1 vs. 3.9) and specialist visits (3.5 vs. 2.5), and disease‐specific ($4820 vs. $2592) costs were significantly higher in the bronchiectasis cohort ( p < 0.05 for all comparisons).
Conclusions
Bronchiectasis is associated with higher comorbid disease‐related healthcare resource utilization and costs and complicates the management of comorbid conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Insmed Incorporated, Bridgewater, New Jersey, USA.
- Cytel, Waltham, Massachusetts, USA.
- University of Nebraska Medical Center, Omaha, Nebraska, USA.
- VA Nebraska Iowa Healthcare System, Omaha, Nebraska, USA.
Förderung
- BLRD VA
- Insmed Incorporated
Zitieren
APA
Mohanty, M., Tang, F., Fastenau, J., Feliciano, J., Lauterio, M., Fucile, S., Haider, M., & Sadikot, R. T. (2025). Impact of Bronchiectasis on Healthcare Resource Utilization and Direct Medical Costs of Managing Comorbid Chronic Obstructive Pulmonary Disease, Asthma, and Rheumatoid Arthritis in the United States. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.70150
Vancouver
Mohanty M, Tang F, Fastenau J, Feliciano J, Lauterio M, Fucile S, et al. Impact of Bronchiectasis on Healthcare Resource Utilization and Direct Medical Costs of Managing Comorbid Chronic Obstructive Pulmonary Disease, Asthma, and Rheumatoid Arthritis in the United States. The Clinical Respiratory Journal. 2025. doi:10.1111/crj.70150
BibTeX
@article{Mohanty2025,
author = {Mohanty, Maitreyee and Tang, Fei and Fastenau, John and Feliciano, Joseph and Lauterio, Melanie and Fucile, Sebastian and Haider, Mahroz and Sadikot, Ruxana T},
title = {Impact of Bronchiectasis on Healthcare Resource Utilization and Direct Medical Costs of Managing Comorbid Chronic Obstructive Pulmonary Disease, Asthma, and Rheumatoid Arthritis in the United States},
journal = {The Clinical Respiratory Journal},
year = {2025},
doi = {10.1111/crj.70150}
}
EUVIMED